Strategic Pharma Partnerships Stablix has established a strategic collaboration with Vertex focused on targeted protein stabilization therapeutics, demonstrating appetite for pharma co-development and licensing. This signals sales opportunities to pursue similar partnerships with large and mid-size players seeking TPS/TDT platforms into additional indications and RESTORAC-like modalities.

R&D Outsourcing Stablix’ platform for targeted protein stabilization and deubiquitination therapeutics suggests a demand for specialized discovery, medicinal chemistry, DMPK, and translational services. Position your CRO/CDMO capabilities to support early discovery through preclinical programs, including assay development, screening, and biomarker work.

Regional Biotech Hub Co-located in New York City and Boston, Stablix sits in two of the world's top biotech hubs with access to leading academic centers, venture networks, and pharma-affiliate ecosystems. Opportunities exist to offer research services, analytics tools, or collaboration models to biotech startups, contract researchers, and academic collaborations seeking TPS/TDT insights.

Regulatory Readiness As Stablix advances toward clinical programs, there will be a need for regulatory strategy, manufacturing information (CMC), and trial execution support. Sales opportunities include regulatory consulting, contract manufacturing coordination, and early access to GMP-grade materials or pilot scale formulation services.

Leadership Network Leadership and board appointments, along with industry recognition, indicate strong networking channels and credibility to accelerate introductions to potential BD partners. Leverage this network to secure executive meetings with pharma BD teams, licensing officers, and strategic investors exploring TPS/TDT opportunities.